As PD-L1 and CD73 are both overexpressed in the tumor microenvironment (TME) and inhibiting CD73 has been shown to enhance anti-PD-L1 efficacy, dual-targeting of PD-L1 and CD73 has emerged as a ...

In a recent review published in Cell Metabolism, researchers present the role of cyclic fasting and fasting-mimicking diets ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported ...

Antennova, a clinical-stage biotech company focused on oncology today announced that the orally administered CD73 small ...

One of BioNTech's first mRNA cancer vaccine candidates has cleared a key mid-stage trial, setting it up for a potential ...

The fight against cancer is seeing a revolutionary shift with the emergence of PD-1/PD-L1 Inhibitors. These groundbreaking ...

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

The INTERLINK-1 trial was testing monalizumab ... looking at its PD-L1 checkpoint inhibitor Imfinzi (durvalumab) plus either monalizumab or anti-CD73 monoclonal antibody oleclumab in patients ...

The overall survival of laryngeal squamous cell carcinoma (LSCC) hasn't changed significantly in the last decades, leading to a negative prognosis in advanced stages. So, the immunotherapy takes space ...

Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine ...